Kodiak Sciences Inc.

Kodiak Sciences Inc. develops retinal medicines using its Antibody Biopolymer Conjugate ("ABC") platform, aiming to prevent and treat major causes of blindness. The company focuses on developing and commercializing next-generation therapeutics for various retinal diseases. Kodiak has three late-stage clinical programs. Its primary investigational medicine, tarcocimab tedromer ("Zenkuda" or "KSI-301"), is an anti-VEGF therapy based on the proprietary ABC platform. Zenkuda has a mean ocular half-life in humans of 20 days, which is approximately three times longer than approved anti-vascular endothelial growth factor ("VEGF") therapies. It is designed to maintain effective drug levels in ocular tissues for longer periods. Zenkuda is being developed as an intravitreal biologic monotherapy, intended to offer a flexible 1-month through 6-month dosing label for all patients with retinal vascular disease, including treatment-naïve, treatment-experienced, mild, and severe patients. Zenkuda has completed four Phase 3 pivotal studies: GLOW1 and GLOW2 for diabetic retinopathy ("DR"), BEACON for retinal vein occlusion ("RVO"), and DAYLIGHT for wet AMD. In the GLOW1 and GLOW2 studies, 100% of patients on extended 6-month dosing at Year 1 successfully treated DR and prevented disease progression. In the BEACON study, Zenkuda-treated patients were dosed at 8-week intervals during the first 6 months, and nearly half of Zenkuda patients did not require treatment in the second 6 months while achieving similar vision and anatomical outcomes as the aflibercept group at one year. The DAYLIGHT study showed non-inferior efficacy and compelling safety and tolerability for Zenkuda at a once-monthly dosing interval.